Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 832 Views
-
Last post by NHE
-
- 0 Replies
- 2422 Views
-
Last post by frodo
-
- 0 Replies
- 1117 Views
-
Last post by NHE
-
- 1 Replies
- 1110 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1402 Views
-
Last post by frodo
-
- 0 Replies
- 1620 Views
-
Last post by NHE
-
- 0 Replies
- 2163 Views
-
Last post by vesta
-
- 0 Replies
- 1646 Views
-
Last post by frodo
-
- 0 Replies
- 2261 Views
-
Last post by DIM